<DOC>
	<DOCNO>NCT00780169</DOCNO>
	<brief_summary>The purpose study assess safety , maximum tolerate dose recommend dose phase II study chemotherapy-combination sorafenib , irinotecan , 5-fluorouracil ( 5-FU ) /folinic acid ( FA ) ( FOLFIRI ) first-line treatment metastatic colorectal cancer .</brief_summary>
	<brief_title>Phase I Trial Sorafenib + FOLFIRI In Metastatic Colorectal Cancer</brief_title>
	<detailed_description>A standard phase I dose escalation design three six patient per dose level use . The first three patient receive chemotherapy dose level 1 4 week ( 2 FOLFIRI regimen ) . The dose escalate next patient one dose level none three patient dose level experience dose-limiting toxicity ( DLT ) first six week . Intrapatient dose escalation allow . If one three patient DLT , additional three patient enrol dose level dose escalate additional patient experience DLT . Otherwise , dose escalation stop , last dose regard Maximum Administered Dose ( MAD ) . The precede dose level declare Maximum Tolerated Dose ( MTD ) . This dose level recommend dose ( RD ) . At least 6 patient treated MTD . The cohort MTD dose level expand many 12 patient gain experience toxicity efficacy Sorafenib + FOLFIRI combination broad patient range . Patients experience DLT first cycle treatment drug withheld . They eligible repeat treatment lower dose treat protocol . Treatment discontinue case serious unmanageable toxicity request patient . Otherwise therapy continue clinically radiologically documented disease progression .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Metastatic colorectal cancer Histopathological verification primary tumor Measurable disease accord RESIST criterion Response Evaluation Criteria Solid Tumors ( ECOG ) performance status â‰¤ 2 Age &gt; 18 year . Women childbearing potential must negative pregnancy test within 7 day prior start treatment . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Patients may prior adjuvant chemotherapy fluoropyrimidines WITHOUT pelvic radiotherapy . Radiation : Patients may prior palliative radiation therapy NO 50 % area bear bone marrow store . Adequate organ marrow function : Hemoglobin &gt; 9.0 g/dl ; absolute neutrophil count ( ANC ) &gt; 1,500/mm3 ; absolute granulocyte count ( AGC ) &gt; 1.5 x 109 /L ; Platelets &gt; 100 x 109 /L ; Serum creatinine creatinine clearance within upper normal limit ; Bilirubin &lt; 1.0 x upper normal limit , &lt; 2.5 x upper normal limit document liver metastasis ; aspartate aminotransferase ( AST ) &lt; 2.5 x upper normal limit , &lt; 5 x upper normal limit document liver metastasis Life expectancy &gt; 3 month Informed consent Previous concurrent malignancy Patients central nervous system ( CNS ) metastases Pregnant lactate woman Concurrent treatment experimental drug anticancer therapy Previous chemotherapy advance and/or metastatic disease Previous adjuvant therapy irinotecan target agent Previous Sorafenib therapy Previous full dose curative pelvic radiotherapy History cardiovascular disease , cerebral ischemia infarction hemorrhage , Gilbert 's disease , HIV positivity Unable compliant procedure protocol Currently use prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>